Sustiva, Stocrin(efavirenz)
Efavirenz, Efavirenz / / Tenofovir Disoproxil, Stocrin, Sustiva, Symfi (efavirenz) is a small molecule pharmaceutical. Efavirenz was first approved as Sustiva on 1998-09-17. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections. It is known to target cytochrome P450 3A4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Efavirenz (discontinued: Efavirenz, Sustiva)
CombinationsEfavirenz, emtricitabine, tenofovir disoproxil, Efavirenz, lamivudine tenofovir disoproxil, Symfi, Symfi lo (discontinued: Atripla, Efavirenz, lamivudine tenofovir disoproxil, Efavirenz; emtricitabine tenofovir disoproxil, Efavirenz; emtricitabine; tenofovir disoproxil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Efavirenz
+
Lamivudine
+
Tenofovir disoproxil fumarate
Efavirenz
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUSTIVA | Bristol Myers Squibb | N-020972 DISCN | 1998-09-17 | 3 products, RLD |
| SUSTIVA | Bristol Myers Squibb | N-021360 DISCN | 2002-02-01 | 2 products, RLD |
Hide discontinued
Efavirenz
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ATRIPLA | Gilead Sciences | N-021937 DISCN | 2006-07-12 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atripla | New Drug Application | 2024-07-09 |
| atripla access | Export only | 2021-04-12 |
| efavirenz | ANDA | 2024-09-05 |
| efavirenz, emtricitabine and tenofovir disoproxil fumarate | ANDA | 2024-06-27 |
| efavirenz, lamivudine and tenofovir disoproxil fumarate | ANDA | 2024-05-07 |
| sustiva | New Drug Application | 2013-01-02 |
| symfi | New Drug Application | 2019-10-15 |
| symfi lo | New Drug Application | 2019-10-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
| hiv | — | D006678 | — |
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
| hepatitis b | — | D006509 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences | |||
| 8598185 | 2029-04-28 | DP | |
| 9018192 | 2026-06-13 | U-750, U-1170 | |
| 9545414 | 2026-06-13 | DP | U-750, U-1170 |
| 8592397 | 2024-01-13 | DP | U-750, U-1170 |
| 8716264 | 2024-01-13 | DP | U-257 |
| 9457036 | 2024-01-13 | DP | U-257 |
| 9744181 | 2024-01-13 | DP | U-257 |
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AG: Non-nucleoside reverse transcriptase inhibitors
— J05AG03: Efavirenz
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR06: Emtricitabine, tenofovir disoproxil and efavirenz
— J05AR11: Lamivudine, tenofovir disoproxil and efavirenz
HCPCS
No data
Clinical
Clinical Trials
475 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 35 | 73 | 103 | 76 | 68 | 342 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 11 | 15 | 27 | 16 | 25 | 91 |
| Hiv | D006678 | — | — | 11 | 12 | 10 | 22 | 22 | 72 |
| Infections | D007239 | EFO_0000544 | — | 9 | 17 | 13 | 9 | 12 | 59 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 5 | 9 | 7 | 9 | 9 | 38 |
| Communicable diseases | D003141 | — | — | 6 | 4 | 6 | 5 | 6 | 26 |
| Healthy volunteers/patients | — | — | — | 17 | — | — | 4 | — | 21 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | 6 | 8 | 4 | 2 | 19 |
| Hepatitis c | D006526 | — | B19.2 | 5 | 3 | 3 | 3 | 6 | 19 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 5 | 2 | 3 | 5 | 5 | 19 |
Show 36 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 2 | — | 1 | 3 |
| Breast feeding | D001942 | — | — | — | — | 1 | — | 1 | 2 |
| Chronic hepatitis | D006521 | — | K73.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 1 | — | — | 2 | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 3 | — | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 2 |
| Arteritis | D001167 | EFO_0009011 | I77.6 | — | 1 | — | — | — | 1 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | — | — | — | 1 |
| Parasitemia | D018512 | — | — | 1 | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 4 | — | — | — | 1 | 5 |
| Neoplasms | D009369 | — | C80 | 3 | — | — | — | — | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Premature obstetric labor | D007752 | — | O60 | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
| Penicillium chrysogenum | D010408 | NCBITaxon_5076 | — | — | — | — | — | 1 | 1 |
| Biological availability | D001682 | — | — | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | — | 1 | 1 |
| Contraception behavior | D003268 | — | — | — | — | — | — | 1 | 1 |
| Sustained virologic response | D000072230 | — | — | — | — | — | — | 1 | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Child behavior | D002652 | — | — | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Efavirenz |
| INN | efavirenz |
| Description | Efavirenz is 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is a benzoxazine, an acetylenic compound, an organochlorine compound, an organofluorine compound and a member of cyclopropanes. |
| Classification | Small molecule |
| Drug class | Fc fusion protein; antivirals: non-nucleoside reverse transcriptase inhibitors; benzoxazinone derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1 |
Identifiers
| PDB | — |
| CAS-ID | 154598-52-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL223228 |
| ChEBI ID | 119486 |
| PubChem CID | 64139 |
| DrugBank | DB00625 |
| UNII ID | JE6H2O27P8 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP3A4
CYP3A4
Organism
Homo sapiens
Gene name
CYP3A4
Gene synonyms
CYP3A3
NCBI Gene ID
Protein name
cytochrome P450 3A4
Protein synonyms
1,4-cineole 2-exo-monooxygenase, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase (sulfoxide-forming), Albendazole sulfoxidase, Cholesterol 25-hydroxylase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, cytochrome P450, family 3, subfamily A, polypeptide 4, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, Cytochrome P450-PCN1, glucocorticoid-inducible P450, Nifedipine oxidase, P450-III, steroid inducible, Quinine 3-monooxygenase, taurochenodeoxycholate 6-alpha-hydroxylase
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Atripla – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Efavirenz
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Efavirenz
+
Emtricitabine
+
Tenofovir
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 21,405 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atripla, Atripla access, Efavirenz, emtricitabine and tenofovir disoproxil fumarate, Efavirenz, lamivudine and tenofovir disoproxil fumarate, Symfi, Symfi lo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
33,228 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use